Journal Browser

► Journal Browser

Special Issue Information

Dear Colleagues,

Hypertension, defined as elevated blood pressure, if the systolic blood pressure is more than 140 mmHg, and or the diastolic blood pressure is higher than 90 mmHg, measured on two different days. Hypertension represents a medical condition that increases significantly risk for cardiovascular, cerebrovascular, and chronic kidney diseases. Besides, it is considered a leading cause of mortality and morbidity worldwide.

The mechanisms underlying the pathological processes of hypertension are not completely clarified. However, relevant evidence correlates the increase of oxidative stress with the development of hypertension. Results of preclinical and clinical studies have demonstrated the crucial role of oxidants compounds and oxidative phenomena in the progression of hypertension. In particular, oxidative stress due to hypertension is associated with endothelial dysfunction in the vessels. Based on World Health Organization guidelines, adults with hypertension requiring treatment from any of three classes of antihypertensive drugs such as thiazide, and thiazide-like agents, angiotensin-converting enzyme inhibitors, or angiotensin-receptor blockers, and long-acting dihydropyridine calcium channel blockers. Since reactive oxygen species are a primary trigger of hypertension, antioxidant therapy would have a favorable effect on hypertension's consequences. In particular, the reduction of oxidative stress could represent a strategy to prevent cardiovascular events in hypertensive patients.

The main goal of this special issue is to highlight different aspects of the involvement of oxidative stress in the development of hypertension, and correlated end-organ damage processes. The special issue will be focused on the mechanisms that would explain this correlation. This issue, therefore, can include publishing preclinical and clinical reports or reviews relating to any of the following topics: hypertension, reactive oxygen species production, oxidative stress, endothelial dysfunction, neurodegeneration, antihypertensive drugs, and their role as antioxidants, antioxidant treatment, or antioxidant supplementation.

We look forward to your contribution.

Dr. Daniele Tomassoni
Dr. Seyed Khosrow Tayebati
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

hypertension
oxidative stress
antioxidant
cardiovascular and cerebrovascular disease
therapy

Published Papers (2 papers)

Download All Papers

Research

Jump to: Review

12 pages, 1148 KiB

Open AccessArticle

Assessment of Oxidative Stress Markers in Hypertensive Patients under the Use of Renin-Angiotensin-Aldosterone Blockers

by Nestor Vazquez-Agra, Ana-Teresa Marques-Afonso, Anton Cruces-Sande, Estefania Mendez-Alvarez, Ramon Soto-Otero, Jose-Enrique Lopez-Paz, Antonio Pose-Reino and Alvaro Hermida-Ameijeiras

Antioxidants 2023, 12(4), 802; https://doi.org/10.3390/antiox12040802 - 25 Mar 2023

Viewed by 1159

Abstract

As in other fields, chronotherapy applied to arterial hypertension (AHT) may have implications on oxidative stress. We compared the levels of some redox markers between hypertensive patients with morning and bedtime use of renin-angiotensin-aldosterone system (RAAS) blockers. This was an observational study that included patients older than 18 years with a diagnosis of essential AHT. Blood pressure (BP) figures were measured using twenty-four-hour ambulatory BP monitoring (24-h ABPM). Lipid peroxidation and protein oxidation were assessed using the thiobarbituric acid reactive substances (TBARS) and reduced thiols assays. We recruited 70 patients with a median age of 54 years, of whom 38 (54%) were women. In hypertensive patients with bedtime use of RAAS blockers, reduced thiol levels showed a positive correlation with nocturnal diastolic BP decrease. TBARS levels were associated with bedtime use of RAAS blockers in dipper and non-dipper hypertensive patients. In non-dipper patients, bedtime use of RAAS blockers was also associated with a decrease in nocturnal diastolic BP. Chronotherapy applied to bedtime use of some BP-lowering drugs in hypertensive patients may be linked to a better redox profile. Full article

(This article belongs to the Special Issue Antioxidant Therapy for Management of Oxidative Stress Induced Hypertension)

► Show Figures

Figure 1

Review

Jump to: Research

20 pages, 1869 KiB

Open AccessReview

Oxidative Stress-Induced Hypertension of Developmental Origins: Preventive Aspects of Antioxidant Therapy

by You-Lin Tain and Chien-Ning Hsu

Antioxidants 2022, 11(3), 511; https://doi.org/10.3390/antiox11030511 - 07 Mar 2022

Cited by 25 | Viewed by 4875

Abstract

Hypertension remains the leading cause of disease burden worldwide. Hypertension can originate in the early stages of life. A growing body of evidence suggests that oxidative stress, which is characterized as a reactive oxygen species (ROS)/nitric oxide (NO) disequilibrium, has a pivotal role in the hypertension of developmental origins. Results from animal studies support the idea that early-life oxidative stress causes developmental programming in prime blood pressure (BP)-controlled organs such as the brain, kidneys, heart, and blood vessels, leading to hypertension in adult offspring. Conversely, perinatal use of antioxidants can counteract oxidative stress and therefore lower BP. This review discusses the interaction between oxidative stress and developmental programming in hypertension. It will also discuss evidence from animal models, how oxidative stress connects with other core mechanisms, and the potential of antioxidant therapy as a novel preventive strategy to prevent the hypertension of developmental origins. Full article

(This article belongs to the Special Issue Antioxidant Therapy for Management of Oxidative Stress Induced Hypertension)

► Show Figures